SCHEMBL3631209

SCHEMBL3631209

CC(OC(=O)c1ccccc1C(=O)O)c1ccccc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
TAS2R14 Q9NYV8 3/20 0.43
ACP3 P15309 1/20 0.40
CNR2 P34972 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
FABP4 P15090 1/20 0.39
ALOX15 P16050 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
LPAR1 Q92633 1/20 0.38
MAPT P10636 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
TP53 P04637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3626019 1.00 ALDH1A1 (0.45) ALDH1A1TAS2R14ACP3CNR2MEN1
SCHEMBL12021827 1.00 ALDH1A1 (0.45) ALDH1A1TAS2R14ACP3CNR2MEN1
Alcohol SCHEMBL3631205 0.95 ALDH1A1 (0.47) ALDH1A1TAS2R14ACP3CNR2MEN1
Alcohol SCHEMBL3626014 0.95 ALDH1A1 (0.47) ALDH1A1TAS2R14ACP3CNR2MEN1
SCHEMBL12021900 0.81 ALDH1A1 (0.48) ALDH1A1ALOX15LMNAGAAHPGD
SCHEMBL3628328 0.81 ALDH1A1 (0.48) ALDH1A1ALOX15LMNAGAAHPGD
SCHEMBL3628211 0.81 ALDH1A1 (0.48) ALDH1A1ALOX15LMNAGAAHPGD
Phthalic Acid SCHEMBL3626023 0.81 TAS2R14 (0.48) ALDH1A1TAS2R14ACP3CNR2MEN1
Phthalic Acid SCHEMBL3626025 0.81 TAS2R14 (0.48) ALDH1A1TAS2R14ACP3CNR2MEN1
SCHEMBL16672680 0.81 LMNA (0.42) ALDH1A1TAS2R14LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1935866-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE FLUOROBENZYL ALCOHOL CENTRAL GLASS CO LTD (JP) 2011-12-14 EP disclosed
EP-1935866-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE FLUOROBENZYL ALCOHOL CENTRAL GLASS CO LTD (JP) 2011-12-14 EP disclosed
US-7795478-B2 Process for producing optically active fluorobenzyl alcohol CENTRAL GLASS COMPANY, LIMITED (JP) 2010-09-14 US disclosed
US-7795478-B2 Process for producing optically active fluorobenzyl alcohol CENTRAL GLASS COMPANY, LIMITED (JP) 2010-09-14 US disclosed
US-7795478-B2 Process for producing optically active fluorobenzyl alcohol CENTRAL GLASS COMPANY, LIMITED (JP) 2010-09-14 US disclosed
US-20090240087-A1 Process for Producing Optically Active Fluorobenzyl Alcohol CENTRAL GLASS COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090240087-A1 Process for Producing Optically Active Fluorobenzyl Alcohol CENTRAL GLASS COMPANY, LIMITED (JP) 2009-09-24 US disclosed
US-20090240087-A1 Process for Producing Optically Active Fluorobenzyl Alcohol CENTRAL GLASS COMPANY, LIMITED (JP) 2009-09-24 US disclosed
EP-1935866-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE FLUOROBENZYL ALCOHOL Central Glass Company, Limited (JP) 2008-06-25 EP disclosed
EP-1935866-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE FLUOROBENZYL ALCOHOL Central Glass Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240087-A1 Process for Producing Optically Active Fluorobenzyl Alcohol ADH1A, ADH1C, ADH5 ALDH1A1 47/4885TAS2R14 4123/4885ACP3 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.